

HEALTHSOUTH CORP  
Form 8-K  
January 07, 2008

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): January 7, 2008**

**HealthSouth Corporation**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**001-10315**  
(Commission File Number)

**63-0860407**  
(I.R.S. Employer  
Identification No.)

**One HealthSouth Parkway, Birmingham, Alabama 35243**

(Address of Principal Executive Officers, Including Zip Code)

**(205) 967-7116**

(Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 7.01. Regulation FD Disclosure.**

In January 2008, representatives of HealthSouth Corporation (the Company) will make presentations at investment banking healthcare industry conferences using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99. The presentation will address, among other things, the Company's current focus on executing its strategic plan and growing earnings per share.

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Note Regarding Presentation of Non-GAAP Financial Measures**

The financial data contained in the presentation includes non-GAAP financial measures, including Adjusted Consolidated EBITDA. The Company continues to believe Adjusted Consolidated EBITDA under its Credit Agreement is a measure of leverage capacity, its ability to service its debt, and its ability to make capital expenditures. However, as the Company continues to deleverage its balance sheet and the large, non-ordinary course charges related to the sins of the past are behind it, this measure will become less significant.

The Company uses Adjusted Consolidated EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company's Credit Agreement, which is discussed in more detail in the Company's Current Report on Form 8-K filed on March 30, 2007 (the March 2007 Form 8-K). These covenants are material terms of the Credit Agreement, and the Credit Agreement represents a substantial portion of the Company's capitalization.

In general terms, the definition of Adjusted Consolidated EBITDA, per the Credit Agreement, allows the Company to add back to Adjusted Consolidated EBITDA all unusual non-cash items or non-recurring items. These items include, but may not be limited to, (1) expenses associated with government, class action, and related settlements, (2) fees, costs, and expenses related to the Company's recapitalization transactions, (3) any losses from discontinued operations and closed locations, (4) charges in respect of professional fees for reconstruction and restatement of financial statements, including fees paid to outside professional firms for matters related to internal controls and legal fees for continued litigation defense and support matters discussed in the March 2007 Form 8-K, (5) compensation expenses recorded in accordance with FASB Statement No. 123(R), *Share-Based Payment*, (6) investment and other income (including interest income), and (7) fees associated with our divestiture activities.

However, Adjusted Consolidated EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America ("GAAP"), and the items excluded from Adjusted Consolidated EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted Consolidated EBITDA should not be considered a substitute for *Net income (loss)* or cash flows from operating, investing, or financing activities. The Company reconciles Adjusted Consolidated EBITDA to *Net income (loss)*, which reconciliation is set forth below and in the presentation, and to *Net cash used in operating activities*, which reconciliation is set forth below. Because Adjusted Consolidated EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted Consolidated EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in the March 2007 Form 8-K.

---

**Reconciliation of Net Income (Loss) to Adjusted Consolidated EBITDA**

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In Millions)</b>			
<b>Net income (loss)</b>	\$ 287.6	\$ (76.1)	\$ 699.2	\$ (553.7)
(Income) loss from discontinued operations	(37.6)	18.0	(475.7)	35.4
Provision for income tax (benefit) expense	(281.1)	2.1	(288.2)	21.0
Loss on interest rate swap	21.4	28.7	6.8	13.9
Interest expense and amortization of debt discounts and fees	60.2	56.8	177.9	176.8
Loss on early extinguishment of debt	2.2		19.9	365.6
Government, class action, and related settlements	3.9	28.4	(31.7)	49.9
Net noncash loss on disposal of assets	0.6	1.1	2.2	5.3
Impairment charges	0.4		15.1	
Depreciation and amortization	19.9	20.7	57.8	63.3
Professional fees accounting, tax, and legal	9.2	23.1	44.3	99.4
Compensation expense under FASB Statement No. 123(R)	2.0	3.6	8.1	11.6
Restructuring activities under FASB Statement No. 146				0.3
Sarbanes-Oxley related costs		0.9	0.3	4.2
<b>Adjusted Consolidated EBITDA</b>	\$ 88.7	\$ 107.3	\$ 236.0	\$ 293.0

---

**Reconciliation of Adjusted Consolidated EBITDA to Net Cash Used in Operating Activities**

	<b>Nine Months Ended</b>	
	<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>
	<b>(In Millions)</b>	
<b>Adjusted Consolidated EBITDA</b>	\$ 236.0	\$ 293.0
Compensation expense under FASB Statement No. 123(R)	(8.1)	(11.6)
Sarbanes-Oxley related costs	(0.3)	(4.2)
Provision for doubtful accounts	26.6	25.9
Professional fees accounting, tax, and legal	(44.3)	(99.4)
Interest expense and amortization of debt discounts and fees	(177.9)	(176.8)
(Gain) loss on sale of investments	(12.3)	0.7
Equity in net income of nonconsolidated affiliates	(7.4)	(6.8)
Minority interests in earnings of consolidated affiliates	23.2	22.8
Amortization of debt discounts and fees	6.1	16.3
Distributions from nonconsolidated affiliates	3.6	4.3
Stock-based compensation	6.1	9.0
Current portion of income tax benefit (expense)	290.9	(8.7)
Change in assets and liabilities	(343.5)	(87.4)
Change in government, class action, and related settlements liability	(110.3)	(87.2)
Other operating cash (used in) provided by discontinued operations	(34.5)	32.6
Other	0.5	(1.8)
<b>Net Cash Used in Operating Activities</b>	<b>\$ (145.6)</b>	<b>\$ (79.3)</b>

***Forward-Looking Statements***

The information contained in the presentation includes certain estimates, projections, and other forward-looking information that reflect the Company's current views with respect to future events and financial performance. These estimates, projections, and other forward-looking information are based on assumptions that the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections, or forward-looking information will be realized.

All such estimates, projections and forward-looking information speak only as of the date hereof. The Company undertakes no duty to publicly update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking information in the presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in our Form 10-Qs for the periods ended March 30, 2007, June 30, 2007, and September 30, 2007, the Annual Report on Form 10-K for the fiscal year ended December 31, 2006, the March 2007 Form 8-K, and in other documents the Company previously filed with the SEC, many of which are beyond the Company's control. These factors may cause actual results to differ materially from the views, beliefs and estimates expressed herein.

**ITEM 9.01. *Financial Statements and Exhibits***

(d) Exhibits  
See Exhibit Index.

Edgar Filing: HEALTHSOUTH CORP - Form 8-K

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHSOUTH CORPORATION

By: /s/ John P. Whittington  
Name: John P. Whittington  
Title: Executive Vice President, General Counsel, and Corporate Secretary

Dated: January 7, 2008

---

**EXHIBIT INDEX**

<u>Exhibit Number</u>	<u>Description</u>
99	Text of slide presentation of HealthSouth Corporation used in connection with the Company's January 2008 presentations at investment banking healthcare industry conferences.